Key clinical point: Terbinafine may be safe during pregnancy, but uncertainty remains.
Major finding: There was no significant difference in major deformity or spontaneous abortion between treatment and no-treatment groups.
Study details: A retrospective analysis of 1,650,649 pregnancies.
Disclosures: No source of funding was disclosed. One of the authors has received grants and personal fees from Novartis. Dr. Murase has received fees from Sanofi Genzyme, Dermira, UCB, Regeneron, Ferndale, and UpToDate.
Andersson MW et al. JAMA Dermatol. 2020 Mar 4. doi: 10.1001/jamadermatol.2020.0142.